IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

Inclusion Criteria: * Age 18 to 75 years, regardless of gender; * Patients with histopathologically confirmed undifferentiated sarcoma (except small round cell undifferentiated sarcoma), synovial sarcoma, angiosarcoma, fibrosarcoma, smooth muscle sarcoma, liposarcoma (except well differentiated liposarcoma), pleomorphic rhabdomyosarcoma, malignant peripheral nerve sheath meningiomas, desmoplastic small round cell tumor, not other specified (NOS), SMARCA4-deficient sarcoma, malignant phyllodes tumor of the breast, intimal sarcoma. * Patients with locally advanced disease that is not amenable to surgery/radiation therapy or with recurrent/metastatic disease; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1; * Expected survival of more than 3 months; * Within 7 days prior to screening (including day 7), laboratory test data requirements: neutrophil count ≥1.5×10⁹/L, platelet count ≥90×10⁹/L, hemoglobin ≥90g/L (no blood transfusion within 14 days), serum total bilirubin ≤1.5 times the upper limit of normal (ULN); ALT and AST ≤2.5× ULN (≤5× ULN for patients with liver metastases); serum creatinine ≤1.5× ULN or creatinine clearance rate ≥50ml/min; * Presence of measurable lesions according to RECIST 1.1 criteria; * The subject (or their legal representative/guardian) must sign an informed consent form, indicating that they understand the purpose of this study, are aware of the necessary procedures, and are willing to participate in this study. E…